Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (151-160 of 198) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trialsMassimo Di Maio, Ciro Gallo, Natasha B Leighl, et al.
Heliyon|August 22, 2024
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterizationLuigi Portella, Giulia Bertolini, Giuseppe Guardascione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2026
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
Clinical Lung Cancer|July 30, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study ResultsFloriana Morgillo, Ester Del Signore, Emilio Bria, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2026
Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
Lung Cancer (Amsterdam, Netherlands)|May 7, 2013
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 studyAlessandro Morabito, Vittorio Gebbia, Massimo Di Maio, et al.
Journal of Translational Medicine|April 1, 2021
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysisMaria Antonietta Isgrò, Maria Grazia Vitale, Egidio Celentano, et al.
BMC Cancer|March 22, 2007
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trialErmelinda De Maio, Carmen Pacilio, Adriano Gravina, et al.
Translational Lung Cancer Research|May 20, 2021
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancerVictoria Foy, Colin R Lindsay, Alexandra Carmel, et al.
Pageof 20

Showing results (151-160 of 198) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trialsMassimo Di Maio, Ciro Gallo, Natasha B Leighl, et al.
Heliyon|August 22, 2024
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterizationLuigi Portella, Giulia Bertolini, Giuseppe Guardascione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2026
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
Clinical Lung Cancer|July 30, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study ResultsFloriana Morgillo, Ester Del Signore, Emilio Bria, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2026
Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
Lung Cancer (Amsterdam, Netherlands)|May 7, 2013
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 studyAlessandro Morabito, Vittorio Gebbia, Massimo Di Maio, et al.
Journal of Translational Medicine|April 1, 2021
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysisMaria Antonietta Isgrò, Maria Grazia Vitale, Egidio Celentano, et al.
BMC Cancer|March 22, 2007
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trialErmelinda De Maio, Carmen Pacilio, Adriano Gravina, et al.
Translational Lung Cancer Research|May 20, 2021
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancerVictoria Foy, Colin R Lindsay, Alexandra Carmel, et al.
Pageof 20